What Next for Circassia Pharmaceuticals PLC Stock After Reaching 52-Week Low?

 What Next for Circassia Pharmaceuticals PLC Stock After Reaching 52 Week Low?

The stock of Circassia Pharmaceuticals PLC (LON:CIR) hit a new 52-week low and has GBX 75.21 target or 11.00% below today’s GBX 84.50 share price. The 8 months bearish chart indicates high risk for the GBX 240.73 million company. The 1-year low was reported on Nov, 3 by Barchart.com. If the GBX 75.21 price target is reached, the company will be worth GBX 26.48M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. The stock increased 1.50% or GBX 1.25 on November 3, hitting GBX 84.5. About 123,531 shares traded hands. Circassia Pharmaceuticals PLC (LON:CIR) has declined 68.20% since April 5, 2016 and is downtrending. It has underperformed by 69.41% the S&P500.

Circassia Pharmaceuticals PLC (LON:CIR) Ratings Coverage

Out of 6 analysts covering Circassia Pharmaceuticals (LON:CIR), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Circassia Pharmaceuticals has been the topic of 26 analyst reports since October 27, 2015 according to StockzIntelligence Inc. The rating was maintained by Cantor Fitzgerald on Tuesday, September 27 with “Hold”. The rating was maintained by Numis Securities with “Buy” on Thursday, April 7. The rating was maintained by Peel Hunt with “Buy” on Friday, March 11. On Tuesday, June 21 the stock rating was downgraded by RBC Capital Markets to “Sector Performer”. The stock of Circassia Pharmaceuticals PLC (LON:CIR) earned “Overweight” rating by JP Morgan on Monday, March 14. The stock of Circassia Pharmaceuticals PLC (LON:CIR) earned “Buy” rating by Stifel Nicolaus on Friday, March 11. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, March 11. The company was maintained on Tuesday, June 21 by JP Morgan. Numis Securities maintained Circassia Pharmaceuticals PLC (LON:CIR) on Friday, March 11 with “Buy” rating. Cantor Fitzgerald downgraded it to “Hold” rating and GBX 110 target price in Monday, July 11 report.

More recent Circassia Pharmaceuticals PLC (LON:CIR) news were published by: Fool.Co.Uk which released: “Can this week’s big fallers bounce back? Circassia Pharmaceuticals plc (-59 …” on June 23, 2016. Also Fool.Co.Uk published the news titled: “Are Royal Mail plc, AG Barr plc and Circassia Pharmaceuticals plc set to soar …” on May 17, 2016. Fool.Co.Uk‘s news article titled: “Should You Buy Hikma Pharmaceuticals Plc, Circassia Pharmaceuticals PLC …” with publication date: July 28, 2015 was also an interesting one.

Circassia Pharmaceuticals plc is a specialty biopharmaceutical firm focused on allergy and respiratory diseases. The company has a market cap of 240.73 million GBP. The Firm operates through three divisions: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide , and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. It currently has negative earnings. The Company’s next-generation immunotherapy is in Phase III testing for cat allergy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment